CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
CAR T therapy beyond cancer: the evolution of a living drug
Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …
patients with untreatable haematologic cancers. These results have energized the field to …
CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up
F Müller, J Taubmann, L Bucci, A Wilhelm… - … England Journal of …, 2024 - Mass Medical Soc
Background Treatment for autoimmune diseases such as systemic lupus erythematosus
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …
T cells in health and disease
L Sun, Y Su, A Jiao, X Wang, B Zhang - Signal transduction and …, 2023 - nature.com
T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Engineered cellular immunotherapies in cancer and beyond
AV Finck, T Blanchard, CP Roselle, G Golinelli… - Nature medicine, 2022 - nature.com
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
A Mackensen, F Müller, D Mougiakakos, S Böltz… - Nature medicine, 2022 - nature.com
Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …
Anti–CD19 CAR T cells in refractory immune thrombocytopenia of SLE
M Li, Y Zhang, N Jiang, C Ning, Q Wang… - … England Journal of …, 2024 - Mass Medical Soc
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE Page 1 The new
england journal of medicine n engl j med 391;4 nejm.org July 25, 2024 376 Correspondence …
england journal of medicine n engl j med 391;4 nejm.org July 25, 2024 376 Correspondence …
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
CD19-targeted CAR T cells in refractory antisynthetase syndrome
Idiopathic inflammatory myopathies are a group of rare, immune-mediated diseases that
primarily affect the skeletal muscle but can also involve other organs such as the lungs, skin …
primarily affect the skeletal muscle but can also involve other organs such as the lungs, skin …